SmartCardia for the Detection of Myocardial Ischemia in Coronary Artery Disease

Overview

Coronary artery disease and myocardial ischemia are among the leading causes of death and disability in the Westerns countries. Timely and accurate diagnosis of myocardial ischemia at the moment of symptom onset is crucial and often delayed. Portable smart medical devices nowadays offers the possibility of ubiquitous self multi-parametric monitoring. Application of such technologies to timely and autonomous detection of myocardial ischemia could be an effective strategy to an earlier and better treatment of symptomatic coronary artery disease. The primary objective is to assess the changes in recorded by the SmartCardia patch (respiratory rate, pulse transit time, heart rate and single ECG trace) during induced ischemia during elective coronary angioplasty procedures. The secondary objective is to asses whether myocardial ischemia can be predicted and quantified by changes in the parameters recorded by SmartCardia patch (respiratory rate, pulse transit time, heart rate and single ECG trace).

Full Title of Study: “Clinical Use of the SmartCardia Wireless Recorder for the Detection of Myocardial Ischemia in the Setting of Coronary Artery Disease: a Single Arm, Prospective Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2021

Detailed Description

Coronary artery disease and myocardial ischemia are among the leading causes of death and disability in the Westerns countries. Timely and accurate diagnosis of myocardial ischemia at the moment of symptom onset is crucial and often delayed. Portable smart medical devices nowadays offers the possibility of ubiquitous self multi-parametric monitoring. Application of such technologies to timely and autonomous detection of myocardial ischemia could be an effective strategy to an earlier and better treatment of symptomatic coronary artery disease. The primary objective is to assess the changes in recorded by the SmartCardia patch (respiratory rate, pulse transit time, heart rate and single ECG trace) during induced ischemia during elective coronary angioplasty procedures. The secondary objective is to asses whether myocardial ischemia can be predicted and quantified by changes in the parameters recorded by SmartCardia patch (respiratory rate, pulse transit time, heart rate and single ECG trace). SmartWearable devices will be applied 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Percutaneous coronary intervention will be conducted following a given protocol (not influencing patient's treatement): 1. Myocardial ischemia will be measured with the Fractional Flow Reserve (FFR) wire during stent expansion (total artery occlusion caused by balloon inflation). This will have no impact on patients' management as the wire will already have been inserted for the diagnostic procedure and will not have an impact on procedure duration. 2. Recording of a 6 leads electrocardiogram during the ischemia phase, which is anyway always available as part of our routine monitoring system. 3. Patients will systematically be asked for any chest pain or discomfort during ischemia (step which is anyway frequently done in standard procedures), to differentiate between clinical and subclinical ischemia. At the end of the procedure, the device will be kept during 30 supplementary minutes while the patient is on standard post percutaneous coronary intervention (PCI) surveillance, thus offering measurements during recovery from ischemia.

Interventions

  • Device: Application of Class II A device SmartCardia
    • Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure

Arms, Groups and Cohorts

  • Experimental: Patients undergoing coronary angiography with planned PCI
    • Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled

Clinical Trial Outcome Measures

Primary Measures

  • Assessment of Ischemia detection
    • Time Frame: During Coronary Revascularisation procedure
    • Assessment of whether myocardial ischemia induced differences would be recorded by the SmartCardia patch by estimating the effect size observed on each individual parameter recorded by the device for each patient, comparing the values measured on pre- and during-ischemia intervals.

Secondary Measures

  • Assessment of ischemia severity
    • Time Frame: During Coronary Revascularisation procedure
    • Establishment of dose-response curve between the recorded parameters by Smart-Cardia and the ischemia severity (based of distal coronary artery pressure)
  • Model description for coloration between ischemia severity and parameters recorded
    • Time Frame: During Coronary Revascularisation procedure
    • Integration of multiple parameters into a more complex model to increase level of correlation between the recorded parameters and the severity of ischemia

Participating in This Clinical Trial

Inclusion Criteria

  • ≥18 years old patients – Known coronary artery disease – Admitted for elective coronary angiography with planned PCI – Informed consent signed Exclusion Criteria:

  • urgent procedure with possible ongoing ischemia before procedure (i.e. STEMI and NSTEMI in the acute phase) – Recent acute coronary syndrome (i.e. STEMI and/or NSTEMI <48h or with persistent ST elevation) – Admission for revascularization of a total chronic occlusion – Known severe valvular disease – Decompensated heart-failure – Decompensated pulmonary condition (such as COPD) – Pregnant and breast-feeding women – Patients with prior CABG – Patients with severe renal failure (eGFR < 30ml/mn) – Vulnerable patients (minors, participants incapable of judgment or participants under tutelage)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Vaudois
  • Provider of Information About this Clinical Study
    • Principal Investigator: Niccolo’ Maurizi, MD, Cardiology Fellow – Centre Hospitalier Universitaire Vaudois
  • Overall Contact(s)
    • Niccolo’ Maurizi, MD, 0041 079 5568 981, niccolo.maurizi@chuv.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.